相似文献
1
Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy.
Br J Dermatol. 2023 Dec 20;190(1):137-138. doi: 10.1093/bjd/ljad324.
2
Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy: reply from the authors.
Br J Dermatol. 2023 Dec 20;190(1):138. doi: 10.1093/bjd/ljad342.
3
Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment.
Br J Dermatol. 2023 Aug 24;189(3):339-341. doi: 10.1093/bjd/ljad149.
4
Anti-PD1 immune checkpoint inhibitor-induced bullous pemphigoid in metastatic melanoma and non-small cell lung cancer.
Cutis. 2020 Jun;105(6):E9-E12.
5
Neutrophil-predominant bullous pemphigoid induced by checkpoint inhibitors: A case series.
J Cutan Pathol. 2020 Aug;47(8):742-746. doi: 10.1111/cup.13687. Epub 2020 Apr 29.
6
Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature.
Dermatol Online J. 2021 Sep 15;27(9). doi: 10.5070/D327955136.
7
Two rare cases of bullous pemphigoid associated with immune checkpoint inhibitors.
BMJ Case Rep. 2022 Dec 7;15(12):e253059. doi: 10.1136/bcr-2022-253059.
8
Methotrexate in the treatment of immune checkpoint blocker-induced bullous pemphigoid.
Eur J Cancer. 2021 Dec;159:34-37. doi: 10.1016/j.ejca.2021.09.032. Epub 2021 Oct 30.
9
Successful Use of Rituximab and Intravenous Gamma Globulin to Treat Checkpoint Inhibitor- Induced Severe Lichen Planus Pemphigoides.
Skinmed. 2020 Aug 1;18(4):246-249. eCollection 2020.
10
Checkpoint inhibitor-induced bullous pemphigoid differs from spontaneous bullous pemphigoid.
J Eur Acad Dermatol Venereol. 2024 Aug;38(8):e722-e728. doi: 10.1111/jdv.19860. Epub 2024 Feb 24.
引用本文的文献
1
Identifying genes associated with Sorafenib resistance in hepatocellular carcinoma to develop risk model.
Discov Oncol. 2025 Aug 20;16(1):1587. doi: 10.1007/s12672-025-03442-x.
2
Skin Reactions and Other Underappreciated Dermatologic Side Effects of Cancer Therapies.
Curr Treat Options Oncol. 2025 Aug 14. doi: 10.1007/s11864-025-01333-5.
3
Immuno-oncologyDupilumab for bullous pemphigoid related to immune checkpoint inhibitors: a retrospective case series.
Oncologist. 2025 Sep 1;30(9). doi: 10.1093/oncolo/oyaf208.
本文引用的文献
1
Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment.
Br J Dermatol. 2023 Aug 24;189(3):339-341. doi: 10.1093/bjd/ljad149.
2
Eosinophil-cationic protein - a novel liquid prognostic biomarker in melanoma.
BMC Cancer. 2019 Mar 7;19(1):207. doi: 10.1186/s12885-019-5384-z.
3
Eosinophils: The unsung heroes in cancer?
Oncoimmunology. 2017 Nov 13;7(2):e1393134. doi: 10.1080/2162402X.2017.1393134. eCollection 2018.
4
Introduction of murine Il-4 gene into B16(F10) melanoma tumors by direct gene transfer with DNA-liposome complexes.
Cancer Lett. 1995 Nov 6;97(2):189-93. doi: 10.1016/0304-3835(95)03961-u.
Zotero 插件